

IN THE CLAIMS

Please cancel the pending claims and add new claims 39-54 as follows:

1-38. (Canceled)

39. (New) A method for inhibiting prostate tumor growth in a mammalian host determined to have or be predisposed to having a metastatic prostate tumor and comprising prostate tumor cells expressing native NKG2D, the method comprising steps:

administering to the mammalian host a composition comprising an NKG2D-binding agent, wherein the NKG2D-binding agent is multivalent and comprises a plurality of non-covalently linked NKG2D-binding moieties of natural NKG2D ligands, wherein the moieties are restricted to a common presenting surface, wherein the common presenting surface is of a host-compatible cell transduced to express the binding moieties, wherein the natural NKG2D ligands are selected from the group consisting of MICA, MICB and ULBP, wherein the administering step is effective to inhibit growth of the tumor; and

detecting a resultant inhibition of growth of the tumor by evaluating growth of the tumor.

40. (New) The method of claim 39, wherein the host is determined to have the tumor.

41. (New) The method of claim 39, wherein the tumor is a primary prostate tumor.

42. (New) The method of claim 40, wherein the tumor is a primary prostate tumor.

43. (New) The method of claim 39, wherein the tumor is a metastasis of a prostate tumor.

44. (New) The method of claim 40, wherein the tumor is a metastasis of a prostate tumor.

45. (New) The method of claim 39, wherein the host-compatible cell is derived from the tumor.

46. (New) The method of claim 40, wherein the host-compatible cell is derived from the tumor.
47. (New) The method of claim 41, wherein the host-compatible cell is derived from the tumor.
48. (New) The method of claim 42, wherein the host-compatible cell is derived from the tumor.
49. (New) The method of claim 43, wherein the host-compatible cell is derived from the tumor.
50. (New) The method of claim 44, wherein the host-compatible cell is derived from the tumor.

B<sup>2</sup> 51. (New) A method for inhibiting primary mammary tumor growth in a mammalian host determined to have or be predisposed to having a primary mammary tumor and comprising mammary tumor cells expressing native NKG2D, the method comprising steps:

administering to the mammalian host a composition comprising an NKG2D-binding agent, wherein the NKG2D-binding agent is multivalent and comprises a plurality of non-covalently linked NKG2D-binding moieties of natural NKG2D ligands, wherein the moieties are restricted to a common presenting surface, wherein the common presenting surface is of a host-compatible cell transduced to express the binding moieties, wherein the natural NKG2D ligands are selected from the group consisting of MICA, MICB and ULBP, wherein the administering step is effective to inhibit growth of the tumor; and

detecting a resultant inhibition of growth of the tumor by evaluating growth of the tumor.

52. (New) The method of claim 51, wherein the host is determined to have the tumor.
53. (New) The method of claim 51, wherein the host-compatible cell is derived from the tumor.
54. (New) The method of claim 52, wherein the host-compatible cell is derived from the tumor.
-